Abstract
The efficacy of allogeneic cultured dermal substitute (CDS) on wound healing was evaluated in six patients with intractable skin ulcers on the lower extremities. Allogeneic CDS was repeatedly applied to wounds at intervals of 4–7 days to prepare a wound bed acceptable for skin grafting or to induce resurfacing through the granulation tissue formation associated with epithelialization. In one patient with a leg ulcer, the wound size decreased to 32% of the original size within 10 weeks and skin grafting was conducted. In the other five patients with leg, ankle, or foot ulcers, the wound size decreased to 9%–25% of the original size within 6 weeks.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yamada N, Shioya N, Kuroyanagi Y. Evaluation of an allogeneic cultured dermal substitute composed of fibroblasts within a spongy collagen matrix as a wound dressing. Scand J Plast Reconstr Surg 1995;29:211–219
Tanaka M, Nakakita N, Kuroyanagi Y. Allogeneic cultured dermal substitute composed of spongy collagen containing fibroblasts: evaluation in animal test. J Biomater Sci Polym Ed 1999;10:433–453
Yamada N, Uchinuma N, Kuroyanagi Y. Clinical evaluation of an allogeneic cultured dermal substitute composed of fibroblasts within a spongy collagen matrix. Scand J Plast Reconstr Surg 1999;33:147–154
Kuroyanagi Y, Yamada N. Yamashita R, Uchinuma E. Tissue-engineered product: allogeneic cultured dermal substitute composed of spongy collagen with fibroblasts. Artif Organs 2001;25:180–186
Kubo K, Kuroyanagi Y. Development of cultured dermal substitute composed of spongy matrix of hyaluronic acid and atelo-collagen combined with fibroblasts: fundamental evaluation. J Biomater Sci Polymer Ed 2003;14:625–641
Kubo K, Kuroyanagi Y. Characterization of cultured dermal substitute composed of spongy matrix of hyaluronic acid and collagen combined with fibroblasts. J Artif Organs 2003;6:138–144
Kubo K, Kuroyanagi Y. Effects of vascular endothelial growth factor released from cultured dermal substitute on proliferation of vascular endothelial cells in vitro. J Artif Organs 2003;6:267–272
Kubo K, Kuroyanagi Y. Development of a cultured dermal substitute composed of a spongy matrix of hyaluronic acid and atelocollagen combined with fibroblasts: cryopreservation. Artif Organs 2004;28:182–188
Kubo K, Kuroyanagi Y. The possibility of long-term cryopreservation of cultured dermal substitute. Artif Organs 2005;29:800–805
Kubo K, Kuroyanagi Y. A study of cytokines released form fibroblasts in culture dermal substitute. Artif Organs 2005;29:845–849
Kuroyanagi Y, Kubo K, Matsui H, Kim H-J, Numari S, Mabuchi Y, Kagawa S. Establishment of banking system for allogeneic cultured dermal substitute. Artif Organs 2004;28:13–21
Culp LA, Murray BA, Rollins BJ. Fibronectin and proteoglycans as determinants of cell-substratum adhesion. J Supramol Struct 1979;11:401–427
Benedetti L, Cortivo R, Berti T, Berti A, Pea F, Mazzo M, Moras M, Abatangelo G. Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomaterials 1993;14:1154–1160
Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagenderived peptides. Proc Natl Acad Sci USA 1978;75:871–875
Clark RA. Continuing medical education: cutaneous tissue repair — basic biologic considerations I. J Am Acad Dermatol 1985;13:701–725
Phillips TJ. Chronic cutaneous ulcers: etiology and epidemiology. J Invest Dermatol 1994;102(6):38S–41S
Kashiwa N, Ito O, Ueda T, Kubo K, Matsui H, Kuroyanagi Y. Treatment of full-thickness skin defect with concomitant grafting of 6-fold extended mesh auto-skin and allogeneic cultured dermal substitute. Artif Organs 2004;28:444–450
Ohtani T, Okamoto K, Kaminaka C, Kishi T, Sakurane M, Yamamoto Y, Ueda K, Kubo K, Kuroyanagi Y, Furukawa F. Digital gangrene associated with idiopathic hypereosinophilia; treatment with allogeneic cultured dermal substitute (CDS). Eur J Dermatol 2004;14:168–171
Moroi Y, Fujita S, Fukagawa S, Mashino T, Goto T, Masuda T, Urabe K, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y, Furue M. Clinical evaluation of allogeneic cultured dermal substitutes for intractable skin ulcers after tumor resection. Eur J Dermatol 2004;14:172–176
Hasegawa T, Suga Y, Mizoguchi M, Ikeda S, Ogawa H, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y. Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in three patients with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 2004;50:803–804
Hasegawa T, Suga Y, Mizoguchi M, Muramatsu S, Minuzo Y, Ogawa H, Kubo K, Kuroyanagi Y. An allogeneic cultured dermal substitute suitable for treating intractable skin ulcers and large skin defects prior to autologous skin grafting: three case reports. J Dermatol 2005;32:715–720
Yonezawa M, Tanizaki H, Inoguchi N, Ishida M, Katoh M, Tachibana T, Miyachi Y, Kubo K, Kuroyanagi Y. Clinical study with allogeneic cultured dermal substitutes for chronic leg ulcers. Int J Dermatol 2007;46(1):36–42
Nishimoto J, Amoh Y, Tanabe K, Niiyama N, Katsuoka K, Kuroyanagi Y. Intractable leg ulcers associated with antiphospholipid syndrome with stasis dermatitis: treatment with allogeneic cultured dermal substitute. Eur J Dermatol 2007:17(4):350–351
Hasegawa T, Suga Y, Mizoguchi M, Muramatsu S, Mizuno Y, Haruna K, Ikeda S, Kuroyanagi Y, Ogawa H. Intractable venous leg ulcer treated successfully with allogeneic cultured dermal substitute. Scand J Plast Reconstr Surg Hand Surg 2007;19:1–3
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamada, N., Uchinuma, E. & Kuroyanagi, Y. Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers of the lower leg. J Artif Organs 11, 100–103 (2008). https://doi.org/10.1007/s10047-008-0406-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10047-008-0406-7